Literature DB >> 14514469

Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice.

Hajime Terao1, Kazuhito Asano, Ken-ichi Kanai, Yoshiyuki Kyo, So Watanabe, Tadashi Hisamitsu, Harumi Suzaki.   

Abstract

BACKGROUND: Low-dose and long-term administration of macrolide antibiotics into patients with chronic airway inflammatory diseases could favorably modify their clinical conditions. However, the therapeutic mode of action of macrolides is not well understood. Free oxygen radicals, including nitric oxide (NO), are well recognized as the important final effector molecules in the development and the maintenance of inflammatory diseases.
PURPOSE: The influence of macrolide antibiotics on NO generation was examined in vivo.
METHODS: Male ICR mice, 5 weeks of age, were orally administered with either roxithromycin, clarithromycin, azithromycin or josamycin once a day for 2-4 weeks. The mice were then injected intraperitoneally with 5.0 mg/kg lipopolysaccharide (LPS) and the plasma NO level was examined 6 h later.
RESULTS: Although pre-treatment of mice with macrolide antibiotics for 2 weeks scarcely affected NO generation by LPS injection, the administration of macrolide antibiotics, except for josamycin, for 4 weeks significantly inhibited LPS-induced NO generation. The data in the present study also showed that pre-treatment of mice with macrolide antibiotics for 4 weeks significantly suppresses not only production of pro-inflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha, but also inducible nitric oxide synthase mRNA expressions, which are enhanced by LPS injection.
CONCLUSION: These results strongly suggest that suppressive activity of macrolide antibiotics on NO generation in response to LPS stimulation in vivo may, in part, account for the clinical efficacy of macrolides on chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514469      PMCID: PMC1781621          DOI: 10.1080/09629350310001599620

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  18 in total

1.  Modulation of Th2 type cytokine production from human peripheral blood leukocytes by a macrolide antibiotic, roxithromycin, in vitro.

Authors:  K Asano; K Kamakazu; T Hisamitsu; H Suzaki
Journal:  Int Immunopharmacol       Date:  2001-10       Impact factor: 4.932

2.  The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids.

Authors:  R M Palmer; L Bridge; N A Foxwell; S Moncada
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

Review 3.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

4.  Azithromycin, the multidrug-resistant protein, and cystic fibrosis.

Authors:  E L Altschuler
Journal:  Lancet       Date:  1998-04-25       Impact factor: 79.321

5.  Protective effect of rebamipide on indomethacin-induced intestinal damage in rats.

Authors:  H Mizoguchi; Y Ogawa; K Kanatsu; A Tanaka; S Kato; K Takeuchi
Journal:  J Gastroenterol Hepatol       Date:  2001-10       Impact factor: 4.029

6.  Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis.

Authors:  Y Ichikawa; H Koga; M Tanaka; M Nakamura; N Tokunaga; M Kaji
Journal:  Chest       Date:  1990-10       Impact factor: 9.410

7.  Protective effect of thiaton, an antispasmodic drug, against indomethacin-induced intestinal damage in rats.

Authors:  Tomonori Kunikata; Tohru Miyazawa; Kenji Kanatsu; Shinichi Kato; Koji Takeuchi
Journal:  Jpn J Pharmacol       Date:  2002-01

8.  Anti-inflammatory activity of macrolide antibiotics.

Authors:  A Ianaro; A Ialenti; P Maffia; L Sautebin; L Rombolà; R Carnuccio; T Iuvone; F D'Acquisto; M Di Rosa
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

Review 9.  Diffuse panbronchiolitis: role of macrolides in therapy.

Authors:  Naoto Keicho; Shoji Kudoh
Journal:  Am J Respir Med       Date:  2002

10.  Influences of roxithromycin on cell-mediated immune responses.

Authors:  S Konno; M Adachi; K Asano; T Kawazoe; K Okamoto; T Takahashi
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

View more
  8 in total

1.  Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity.

Authors:  Vanesa Ivetić Tkalčević; Snježana Cužić; Miroslava Dominis Kramarić; Michael J Parnham; Vesna Eraković Haber
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

2.  Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii.

Authors:  Koichi Yamada; Katsunori Yanagihara; Norihito Kaku; Yosuke Harada; Yohei Migiyama; Kentaro Nagaoka; Yoshitomo Morinaga; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Hiroo Hasegawa; Hiroshige Mikamo; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

3.  Azithromycin in Combination with Ceftriaxone Reduces Systemic Inflammation and Provides Survival Benefit in a Murine Model of Polymicrobial Sepsis.

Authors:  Anasuya Patel; Jiji Joseph; Hariharan Periasamy; Santosh Mokale
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro.

Authors:  Ayako Furuya; Kazuhito Asano; Naruo Shoji; Kojiro Hirano; Taisuke Hamasaki; Harumi Suzaki
Journal:  J Inflamm (Lond)       Date:  2010-11-23       Impact factor: 4.981

5.  The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells.

Authors:  Nadine Lusamba Kalonji; Kazuhiro Nomura; Tetsuaki Kawase; Chiharu Ota; Hiroshi Kubo; Takeya Sato; Teruyuki Yanagisawa; Toshiaki Sunazuka; Satoshi Ōmura; Mutsuo Yamaya
Journal:  Physiol Rep       Date:  2015-10

Review 6.  Macrolide therapy in chronic inflammatory diseases.

Authors:  Brygida Kwiatkowska; Maria Maślińska
Journal:  Mediators Inflamm       Date:  2012-08-21       Impact factor: 4.711

7.  Low-dose, long-term macrolide therapy in asthma: An overview.

Authors:  Umur Hatipoglu; Israel Rubinstein
Journal:  Clin Mol Allergy       Date:  2004-03-16

8.  Ivermectin (IVM) Possible Side Activities and Implications in Antimicrobial Resistance and Animal Welfare: The Authors' Perspective.

Authors:  Cristian Piras; Enrico Gugliandolo; Fabio Castagna; Ernesto Palma; Domenico Britti
Journal:  Vet Sci       Date:  2022-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.